Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Iovance Biotherapeutics Inc
(NQ:
IOVA
)
10.24
-0.19 (-1.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Iovance Biotherapeutics Inc
< Previous
1
2
3
Next >
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is One of Friday Morning’s Most Active Stocks
September 15, 2023
Via
Investor Brand Network
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
September 14, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
September 07, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 18, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
August 08, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
July 25, 2023
Oral Presentation of Cohort 3A Data from IOV-COM-202 Phase 2 Clinical Trial of LN-145 in Combination with Pembrolizumab in Anti-PD1-naïve Advanced (metastatic or unresectable) Non-Small Cell Lung...
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
July 24, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 21, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
July 13, 2023
Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 3 Million Shares of Common Stock
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
June 20, 2023
Investor Conference Call and Webcast on June 26 at 5:00 p.m. ET
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
How to Trade Stocks Online the Right Way
June 13, 2023
Learning how active trading works requires serious education, including learning how to get started. Learn how to trade stocks online on MarketBeat.
Via
MarketBeat
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
June 09, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
May 30, 2023
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
Via
MarketBeat
Topics
Death
Exposures
Death
Product Safety
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
May 26, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 09, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
May 02, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
April 24, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
March 24, 2023
First TIL Therapy BLA Submission to U.S. Food and Drug Administration
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
March 01, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
February 28, 2023
First Biologics License Application (BLA) Submission on Track to Complete in 1Q23
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
February 21, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
January 23, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
November 30, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
November 18, 2022
BLA Submission Ongoing with U.S. Food and Drug Administration
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
November 03, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.